CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective – Cancer Therapy Advisor
Cancer Therapy Advisor |
CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
Cancer Therapy Advisor A US Food and Drug Administration (FDA) panel recently recommended the approval of CTL019 chimeric antigen receptor (CAR) T cell therapy for acute lymphoblastic leukemia (ALL). This first-ever recommendation for a CAR T therapy was based on … |
